Last reviewed · How we verify
NCT07331142
CBD Stenting vs Non-Stenting for Choledocholithiasis
NA trial testing Temporary Plastic Biliary Stent Placement in Choledocholithiasis in 200 participants. Completed in 1 November 2025.
1 August 2025
Quick facts
| Lead sponsor | National Liver Institute, Egypt |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 200 |
| Start date | 1 March 2024 |
| Primary completion | 1 August 2025 |
| Estimated completion | 1 November 2025 |
| Sites | 1 location across Egypt |
Drugs / interventions tested
- Temporary Plastic Biliary Stent Placement
- Endoscopic Retrograde Cholangiopancreatography with Stone Clearance
Conditions studied
- Choledocholithiasis — all drugs for Choledocholithiasis →
Sponsor
National Liver Institute, Egypt
Who can join
Adults 18 to 75, any sex, with Choledocholithiasis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The role of prophylactic biliary stenting after complete clearance of common bile duct stones in patients awaiting cholecystectomy remains controversial. This randomized controlled trial investigates whether temporary plastic biliary stent placement after documented complete choledocholithiasis clearance reduces the recurrence of choledocholithiasis and biliary complications in patients awaiting cholecystectomy for concomitant cholelithiasis. Between March 2024 and September 2025, 200 patients with concomitant cholelithiasis and choledocholithiasis were randomized to either prophylactic biliary stenting (n=100) or no stenting (n=100) after complete stone clearance documented on occlusion cholangiogram during endoscopic retrograde cholangiopancreatography (ERCP). The primary outcome was symptomatic choledocholithiasis recurrence within 3 months. Secondary outcomes included biliary complications (cholangitis, cholecystitis, post-ERCP pancreatitis, bleeding), radiation exposure metrics, and cost-effectiveness.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07331142
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Choledocholithiasis
Currently open trials in the same condition.
- NCT07001423 — ChOlecystectomy aFter successFul Endoscopic Common Bile Duct Stone Extraction in Elderly · NA · recruiting
- NCT07008170 — Laparoendoscopic Rendezvous for Concomitant Gall Bladder Stones and Common Bile Duct Stones · NA · recruiting
- NCT07130864 — Early vs Late Laparoscopic Cholecystectomy After Common Bile Duct Stones Clearance Through Ercp. · NA · recruiting
- NCT07503964 — The Significance of Laparoscopic Transcystic Papilla Vateri Balloon Dilatation in Patients With Choledocholithiasis. · NA · active not recruiting
- NCT07407491 — Comparative Efficacy Of Intraductal Antibiotic During ERCP In Acute Cholangitis · Phase 2 · recruiting
Other National Liver Institute, Egypt trials
Trials by the same sponsor.
- NCT06948279 — Immediate vs. Elective Endoscopic Removal of Large CBD Stones in High-Risk Elderly Patients · NA · completed
- NCT07337291 — Double Stent for Biliary Stones in Cirrhotic Patients · NA · completed
- NCT05184491 — Nitazoxanide and Lansoprazole Based Regimens for H. Pylori Management · Phase 4 · unknown
- NCT06384443 — Proton Pump Inhibitors in Cirrhotic Patients · completed
- NCT04043858 — Safety and Efficacy of Midodrine Hydrochloride in the Management of Refractory Ascites Due to Cirrhosis in Children · NA · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07331142 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by National Liver Institute, Egypt
- Last refreshed: 9 January 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07331142.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing